Show simple item record

dc.contributor.authorBacolod, Manny D.
dc.contributor.authorHuang, Jianmin
dc.contributor.authorGiardina, Sarah F.
dc.contributor.authorFeinberg, Philip B.
dc.contributor.authorMirza, Aashiq H.
dc.contributor.authorSwistel, Alexander
dc.contributor.authorSoper, Steven A.
dc.contributor.authorBarany, Francis
dc.date.accessioned2020-06-16T19:33:40Z
dc.date.available2020-06-16T19:33:40Z
dc.date.issued2020-01-31
dc.identifier.citationBacolod, M. D., Huang, J., Giardina, S. F., Feinberg, P. B., Mirza, A. H., Swistel, A., Soper, S. A., & Barany, F. (2020). Prediction of blood-based biomarkers and subsequent design of bisulfite PCR-LDR-qPCR assay for breast cancer detection. BMC cancer, 20(1), 85. https://doi.org/10.1186/s12885-020-6574-4en_US
dc.identifier.urihttp://hdl.handle.net/1808/30514
dc.descriptionThis work is licensed under a Creative Commons Attribution 4.0 International License.en_US
dc.description.abstractBackground Interrogation of site-specific CpG methylation in circulating tumor DNAs (ctDNAs) has been employed in a number of studies for early detection of breast cancer (BrCa). In many of these studies, the markers were identified based on known biology of BrCa progression, and interrogated using methyl-specific PCR (MSP), a technique involving bisulfite conversion, PCR, and qPCR.

Methods In this report, we are demonstrating the development of a novel assay (Multiplex Bisulfite PCR-LDR-qPCR) which can potentially offer improvements to MSP, by integrating additional steps such as ligase detection reaction (LDR), methylated CpG target enrichment, carryover protection (use of uracil DNA glycosylase), and minimization of primer-dimer formation (use of ribose primers and RNAseH2). The assay is designed to for breast cancer-specific CpG markers identified through integrated analyses of publicly available genome-wide methylation datasets for 31 types of primary tumors (including BrCa), as well as matching normal tissues, and peripheral blood.

Results Our results indicate that the PCR-LDR-qPCR assay is capable of detecting ~ 30 methylated copies of each of 3 BrCa-specific CpG markers, when mixed with excess amount unmethylated CpG markers (~ 3000 copies each), which is a reasonable approximation of BrCa ctDNA overwhelmed with peripheral blood cell-free DNA (cfDNA) when isolated from patient plasma. The bioinformatically-identified CpG markers are located in promoter regions of NR5A2 and PRKCB, and a non-coding region of chromosome 1 (upstream of EFNA3). Additional bioinformatic analyses would reveal that these methylation markers are independent of patient race and age, and positively associated with signaling pathways associated with BrCa progression (such as those related to retinoid nuclear receptor, PTEN, p53, pRB, and p27).

Conclusion This report demonstrates the potential utilization of bisulfite PCR-LDR-qPCR assay, along with bioinformatically-driven biomarker discovery, in blood-based BrCa detection.
en_US
dc.publisherBMCen_US
dc.rights© The Author(s) 2020.en_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectBreast canceren_US
dc.subjectMethylationen_US
dc.subjectEarly detectionen_US
dc.subjectLigase detection reactionen_US
dc.subjectBiomarkeren_US
dc.titlePrediction of blood-based biomarkers and subsequent design of bisulfite PCR-LDR-qPCR assay for breast cancer detectionen_US
dc.typeArticleen_US
kusw.kuauthorSoper, Steven A.
kusw.kudepartmentMechanical Engineeringen_US
dc.identifier.doi10.1186/s12885-020-6574-4en_US
dc.identifier.orcidhttps://orcid.org/0000-0002-2085-4877en_US
kusw.oaversionScholarly/refereed, publisher versionen_US
kusw.oapolicyThis item meets KU Open Access policy criteria.en_US
dc.identifier.pmidPMC6995062en_US
dc.rights.accessrightsopenAccessen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© The Author(s) 2020.
Except where otherwise noted, this item's license is described as: © The Author(s) 2020.